Search 

Arcinova is an agile Contract Development & Manufacturing Organisation (CDMO), providing the pharmaceutical industry with integrated and specialist services, throughout the drug development pipeline.
 
At Arcinova we deliver high quality end-to-end solutions by combining the disciplines of chemistry, biology and bioinformatics in one world-class 15,000m2 facility. We focus on process, research, development, scale-up and small scale manufacturing, including bioanalysis, regulatory and consulting services.
 
We are a trusted partner for our customers, we support their development and delivery programmes for new medicines in a timely and cost-effective manner to sustainably improve the health and wellbeing of society.
 
Our mission at Arcinova is to deliver best-in-class technology services in the fields of contract research, development and small scale manufacturing whilst minimising risk and overall cost.

Partnering to Advance Human Health

A unique culture delivering exceptional solutions:
Almac is a financially secure, privately owned organisation with 5,000 employees located within the US, Europe and Asia. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 50 years.

Aspire Pharma is an innovative, privately owned British pharmaceutical company established in 2009. We develop medicines that make a difference. Our innovative products are difficult to emulate and are the result of teamwork and creative thought.

bit.bio is an award-winning human synthetic biology enterprise. Our mission is to code cells to advance the wellbeing of humanity. To do so, we apply the principles of computation to biology.

Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.

To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy.

Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).

The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Applications of our mSAS® (modified Supercritical Anti-Solvent) technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

• Crystal and particle engineering

• Stabilisation of therapeutic agents derived from biotechnology

• Polymorph screening

• Improved performance of poorly soluble drugs

• Improved bioavailabilty of small molecules

• Alternative routes of delivery such as inhaled therapy

• Taste masking

• Crystallisation seeds

• Residual solvent elimination

Diurnal is an innovative UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

Since our inception in 2004, our company mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients’ quality of life.

Diurnal has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.